Alejandro González Veliz: Does Elevated Lp(a) Always Mean the Same Cardiovascular Risk?
Alejandro González Veliz, Interventional Cardiologist at Institute of Cardiology and Cardiovascular Surgery, shared a post on LinkedIn about recent article by Niekbachsh Mohammadnia et al., published in JAMA Cardiology, adding:
“Does elevated Lp(a) always mean the same cardiovascular risk?
This new JAMA Cardiology study suggests the answer is no.
Among more than 43,000 individuals followed for over 13 years, IL-6 emerged as the only inflammatory biomarker that significantly modified the association between elevated Lp(a) and incident coronary artery disease.
Patients with both high Lp(a) and high IL-6 had substantially greater coronary risk, whereas elevated Lp(a) alone carried much less excess risk when IL-6 levels were low.
Interestingly, this interaction was not observed for aortic stenosis, suggesting different biological mechanisms despite Lp(a) being a shared risk factor.
These findings reinforce the concept that cardiovascular prevention may increasingly rely on combining lipid biology with inflammatory profiling, potentially helping identify those who could derive the greatest benefit from emerging Lp(a)-lowering and anti-inflammatory therapies.
What do you think will become the next essential biomarker in preventive cardiology: IL-6, hsCRP, or something else?”
Title: Lipoprotein(a), Inflammation, and Risk of Coronary Artery Disease and Aortic Valve Stenosis
Authors: Niekbachsh Mohammadnia, Linke Li, Daniel Ezzat, Zhi Yu, Vineet K. Raghu, Jennifer L. Halford, Niels P. Riksen, Pradeep Natarajan, Jan H. Cornel, Michael C. Honigberg, Saloua El Messaoudi
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis